On April 22nd, 2025, EverBridge Group and Cardiocycle Medical Technology (Suzhou) Co., Ltd. ("Cardiocycle") announced a strategic partnership.

The collaboration between EverBridge Group and Cardiocycle focuses on two key areas: interventional oncology and peripheral vascular.

As for interventional oncology, this collaboration will focus on product portfolio of B-TACE (Balloon-occluded transcatheter arterial chemoembolization), aiming to deliver more targeted and effective “one-stop” solution for advanced-stage cancer patients. As for peripheral vascular, this collaboration will provide leading solution for large size vascular access, addressing.

EverBridge Group will serve as the strategic partner for the Greater China Region (including Hong Kong, Macau and Taiwan)，being responsible for full-spectrum commercialization of related products, and actively explore more advanced collaboration model. The partnership will leverage complementary strengths to accelerate innovation and market penetration in  interventional oncology and peripheral vascular areas.

This collaboration strengthens EverBridge Group’s portfolio in oncology and peripheral vascular pipeline. Moving forward, we are willing to further broaden and deepen the applications of interventional treatment, thereby delivering enhanced treatment options worldwide.